Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20828351 | 0.81 | CYP2C19 (0.48) | CYP2C19CYP1A2GAAMAPTNPC1 | |
| SCHEMBL2182186 | 0.80 | CNR2 (0.36) | SLC6A3 | |
| SCHEMBL17295745 | 0.80 | RAB9A (0.39) | SMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL12527632 | 0.80 | CYP2C19 (0.46) | CYP2C19CYP1A2GAAMAPTNPC1 | |
| SCHEMBL1403468 | 0.78 | CYP2C19 (0.55) | CYP2C19SMN1; SMN2CYP1A2GAAMAPT | |
| SCHEMBL2182205 | 0.77 | ABL1 (0.37) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL15496889 | 0.77 | CYP2C19 (0.54) | CYP2C19SMN1; SMN2CYP1A2GAAMAPT | |
| SCHEMBL19874404 | 0.76 | RAB9A (0.43) | SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL19874327 | 0.76 | RAB9A (0.45) | SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL17479485 | 0.75 | MEN1 (0.46) | CYP2C19SMN1; SMN2CYP1A2GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166132-A1 | Gamma Secretase Modulators | AMGEN INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2231602-A1 | GAMMA SECRETASE MODULATORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009075874-A1 | GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166132-A1 | Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | CYP2C19 4369/4885SMN1; SMN2 1335/4885CYP1A2 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.